Deals
Going private could give Recordati strategic flexibility and a stable source of capital, according to CVC Capital Partners and Groupe Bruxelles Lambert, which are offering to take the Italian pharma private for a 13% premium.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Creoptix AG announced that is has raised CHF 8 million in the first closing as part of a Series C financing round.
Arctoris Ltd, a fully automated drug discovery platform for virtual and traditional biotechnology companies, pharmaceutical corporations and academia, announced that it has successfully closed a seed funding round of £3.2 million to advance its novel drug discovery offering.
Novo Seeds, the company creation team of Novo Holdings, announced that it has co-led the €20 million Series A financing round in STipe Therapeutics (STipe).
Synairgen plc, the respiratory drug discovery and development company, announces its unaudited interim results for the six months ended 30 June 2019.
Centauri Therapeutics, an immunotherapy company active in oncology and infectious diseases, announces that it will attend the following scientific and investor conferences
Beam, which is one of BioSpace’s NextGen Bio “Class of 2019” Life Science Startups to Watch in 2019, filed its IPO plans with the U.S. Securities and Exchange Commission on Friday.
Shares of Dova Pharmaceuticals are up more than 38% in premarket trading after Sobi announced its intentions to acquire the company for $915 million.
Companies’ complementary strengths in data and cloud technology to improve healthcare efficiency and patient outcomes
T3 Pharmaceuticals AG, a Basel-based company focusing on immuno-oncology, closes its second financing round of over 12M CHF with existing investors joined by Boehringer Ingelheim Venture Fund and Reference Capital SA.
Led by ARTIS Ventures, Funding will Drive Further Research and Commercialization of Eko’s Machine Learning Platform